News

FDA clears portable hematology analyzer


 

PixCell Medical

HemoScreen Photo courtesy of

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for PixCell Medical’s HemoScreen™.

This portable hematology analyzer is used to perform a complete blood count at the point of care.

HemoScreen requires a single drop of blood and uses disposable cartridges that provide automatic sample preparation.

HemoScreen can analyze 20 standard complete blood count parameters and produces results within 5 minutes.

Study results suggested that HemoScreen provides results comparable to those of another hematology analyzer, Sysmex XE-2100. This study was published in the Journal of Clinical Pathology in 2016.

“The HemoScreen delivers lab-accurate results,” said Avishay Bransky, PhD, chief executive officer of PixCell Medical.

He added that HemoScreen “would be especially useful” in physicians’ offices, emergency rooms, intensive care units, oncology clinics, and remote locations.

HemoScreen makes use of a technology called viscoelastic focusing, which employs microfluidics and machine vision algorithms to analyze cells.

Recommended Reading

Underused PV treatments save lives, doc says
MDedge Hematology and Oncology
CPI-0610 receives fast track designation for MF
MDedge Hematology and Oncology
Adoptive T-cell therapy treats PML
MDedge Hematology and Oncology
The challenges of diagnosing CMML
MDedge Hematology and Oncology
Genomic findings may predict outcomes in MPN patients
MDedge Hematology and Oncology
GPS appears to predict survival in myelofibrosis
MDedge Hematology and Oncology
AMP publishes report on DNA variants in CMNs
MDedge Hematology and Oncology
Familial risk of myeloid malignancies
MDedge Hematology and Oncology
Tool may reveal optimal time for SCT in MF
MDedge Hematology and Oncology
JAK inhibition linked to B-cell lymphoma
MDedge Hematology and Oncology